Evofem bags $25M to back novel contraceptive methods

att woman with phone

Evofem, a biotechnology company focused on women’s reproductive health, has closed on a Series D round of preferred stock financing that will amount to $25 million from Woodford Investment Management.

The San Diego, CA based startup counts among its products Amphora and Nestorone/Ethinyl Estradiol Ring (NES/EE), which are both currently in development.

Amphora has completed a Phase III clinical trial as a contraceptive and Evofem has submitted an application to the FDA for Amphora as a non-hormonal vaginal gel to be used as a contraceptive. There is ongoing work to look into Amphora having microbicidal properties.

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

"We are pleased that Woodford Investment Management recognizes the potential of our contraceptive technology which offers a meaningful alternative to women who desire non-hormonal contraception," said Saundra Pelletier, Evofem CEO, in a statement.

She continued, "Empowering women with access to innovative contraceptive options is the core of our business. We understand that women have changing needs regarding their reproductive choices and we want to offer non-hormonal, woman-controlled solutions."

NES/EE has gone through clinical trials and has shown it can be successfully used as a long-acting method of contraception that can be fully controlled.

Evofem is also developing other reproductive health options for women which aim to be non-hormonal, woman-controlled, on-demand and rapidly-reversible.

- here's the press release

Related Articles:
Study finds injectable birth control causes significant weight gain and changes in body mass

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.